Reading KYNB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KYNB free→Reading KYNB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KYNB free→QuarterlyIQ Insights · KYNB
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(24.5) + peer(0.2*5.8) + term(0.0) → 9.74% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On May 11, 2026, Kyntra Bio, Inc. (“Kyntra Bio”) issued a press release announcing financial results for the quarter ended March 31, 2026. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the lia…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On March 16, 2026, Kyntra Bio, Inc. (“Kyntra Bio”) issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subj…
Results of Operations and Financial Condition. On November 10, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to th…
Results of Operations and Financial Condition. On August 11, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabi…
Results of Operations and Financial Condition. On May 12, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended March 31, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabili…
Results of Operations and Financial Condition. On March 17, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter and year ended December 31, 2024. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject…
Results of Operations and Financial Condition. On February 20, 2025, we announced that as of December 31, 2024, we estimated that we had approximately $121.1 million in cash, cash equivalents, and accounts receivable. This preliminary financial information is unaudited and is based on currently available information and does not present all necessary information for an understanding of our financial condition as of December 31, 2024 or our results of operations for the year ended December 31,…